The Biotech Growth Trust PLC commences an Equity Buyback Plan for 2,710,338 shares, representing 14.90% of its issued share capital, under the authorization approved on November 12, 2025.

The Biotech Growth Trust PLC (LSE:BIOG) commences share repurchases on November 14, 2025, under the program mandated by the shareholders in the Annual General Meeting held on November 12, 2025. As per the mandate, the company is authorized to repurchase up to 2,710,338 shares, representing 14.90% of its issued share capital. The minimum price (exclusive of expenses) which may be paid for each ordinary share is £0.25 and the maximum price which may be paid for each ordinary share is the higher an amount equal to 105% of the average of the middle market quotations for an ordinary share as derived from the London Stock Exchange Daily Official List of the UK Listing Authority for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased and an amount equal to the higher of the price of the last independent trade of an ordinary share and the current highest independent bid for an ordinary share as derived from the London Stock Exchange Trading System.

The shares purchased may either be cancelled or held as treasury shares, which may then be cancelled, resold or transferred. The authority shall expire at the conclusion of the next Annual General Meeting of the company or 15 months, whichever is earlier. As of November 12, 2025, the company had 21,956,234 ordinary shares in issue.